EGFR and non-small cell lung carcinoma: In addition, in vivo, B cell–derived IL-35 (via a STING–IL-35 axis) was shown to reduce NK proliferation and blunt NK-driven antitumor immunity in murine tumor models (10).While IL-35 has been implicated in suppressing various immune cell functions, its specific impact on NK cell activity in the context of EGFR-mutant NSCLC remains largely unknown.